What To Expect From PFE Stock In 2025?

1. PFE stock fell 5% in 2024, lagging behind the S&P 500. 2. Covid-19 vaccine sales decline affects Pfizer’s profitability. 3. Vyndaqel and Eliquis showed strong sales growth, offsetting some losses. 4. Pfizer's debt declined to $67 billion, while cash decreased to $10 billion. 5. Xeljanz faces patent expiration in 2025, creating potential revenue concerns.